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Abstract: Biocatalysis offers an alternative approach to conventional chemical processes for the
production of single-isomer chiral drugs. Lipases are one of the most used enzymes in the synthesis
of enantiomerically pure intermediates. The use of this type of enzyme is mainly due to the
characteristics of their regio-, chemo- and enantioselectivity in the resolution process of racemates,
without the use of cofactors. Moreover, this class of enzymes has generally excellent stability in
the presence of organic solvents, facilitating the solubility of the organic substrate to be modified.
Further improvements and new applications have been achieved in the syntheses of biologically
active compounds catalyzed by lipases. This review critically reports and discusses examples
from recent literature (2007 to mid-2015), concerning the synthesis of enantiomerically pure active
pharmaceutical ingredients (APIs) and their intermediates in which the key step involves the action
of a lipase.
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1. Introduction
Among the applications of lipases, the synthesis of enantiomerically pure active pharmaceutical
ingredients (APIs) and their intermediates using these enzymes is a subject of continuing interest. It is
noteworthy that most of the drugs are chiral, and it is important to know which stereoisomer has the
desired biological activity. Thus, only the active stereoisomer is administered, thereby preventing the
patient receiving a dose of stereoisomer with unnecessary activity. Such practice avoids unnecessary
consumption of the substance and minimizes side effects. Biocatalysis offers an alternative approach
to conventional chemical processes for the production of enantiomerically pure chiral drugs. Lipases
are highlighted as being among the most frequently used enzymes for the production of drugs and
their intermediates, a subject covered in an elegant review in 2006 [1]. The use of lipases is mainly
due to the characteristics of the regio-, chemo- and enantioselectivity in the resolution process of
racemates, without the use of cofactors. Moreover, this class of enzymes has generally excellent
stability in the presence of organic solvents, facilitating the solubility of the organic substrate to be
modified [1]. Some reviews on the preparation of APIs via biocatalysis were also published, but
involved various types of enzymes and not only lipases [2–6].
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On this topic, we will present representative examples of recent reports in the literature (2007
to mid-2015) concerning the lipase-catalyzed preparation of APIs and their intermediates through
hydrolytic (Section 2) and esterification (Section 3) approaches. Additionally, examples involving
both approaches as complementary methods are discussed (Section 4).
2. Hydrolytic Approach
Hydrolysis of racemic or prochiral esters catalyzed by lipases for preparing an enantiomerically
pure drug intermediate is a well-established method in organic chemistry; nevertheless, new
applications, new enzymes, and improved techniques for bettering the efficiency of already known
lipase-catalyzed hydrolysis are continuously proposed.
2.1. Key Intermediates of Paclitaxel Side Chain
An interesting example of the application of lipases for preparing a series of useful chiral
intermediates was proposed for the chemoenzymatic synthesis of analogues of Paclitaxel (trade
names: Taxol or Onxal). This compound is a polyoxygenated diterpenoid isolated from the bark
of Taxus brevifolia, which has been extensively used in anti-cancer therapy. A number of compounds
from the class of arylazetidiones, precursors of the amino acid side chain of Paclitaxel, as well as a
new generation of taxanoides side chains, were prepared in enantiomerically pure form by kinetic
resolution, via hydrolysis, of the corresponding esters in the presence of lipases. A screening was
performed with 14 lipases, and four of them (PS (Burkholderia cepacia), PS-C (B. cepacia immobilized
on ceramics), AS (Aspergillus niger), and ABL (Arthrobacter sp.)) showed positive results. Among
these lipases, Arthrobacter sp. (ABL) was the only one that hydrolyzed all tested substrates. ABL was
used on the resolution of four arylazetidiones derivatives (Scheme 1) in buffer solution pH 7.0, in the
presence of co-solvents such as acetonitrile (MeCN), dimethylformamide (DMF) or dimethylsulfoxide
(DMSO), and resulted in enantiomeric excess of both alcohols and acetates of >99% and conversions
close to 50% [7].
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The compound (2R,3S)-3-phenylisoserine is also a key intermediate of the Paclitaxel side chain, 
and it has been already produced by biocatalytical methods [8]. The racemate of ethyl 3-amino-3-
phenyl-2-hydroxy-propionate (3-phenylisoserine ethyl ester) was synthesized and resolved via 
lipase-mediated kinetic hydrolysis. Various lipases were screened and the best result (c 50%, E > 200) 
was obtained with lipase from B. cepacia immobilized on diatomaceous earth (PS IM). After 
optimizing the reaction conditions (diisopropyl ether (DIPE) with 0.5 eq. H2O as solvent, 50 °C), 3 h, 
the (2R,3S)-3-amino-3-phenyl-2-hydroxy-propionate was obtained with 100% ee, c 50% and E > 200. 
Subsequent hydrolysis of this latter compound led to (2R,3S)-3-phenylisoserine (Scheme 2a). One 
advantage of this strategy is that it was not necessary to protect the amino group [9]. 
Another strategy to produce the (2R,3S)-3-phenylisoserine involved the enantioselective ring-cleavage  
of (3R*,4S*)-β-lactam (R=H) and its 3-acetoxy derivative (R=Ac) using CAL-B (lipase B from  
Candida antarctica produced by the submerged fermentation of a genetically modified Aspergillus oryzae 
and absorbed on a macroporous resin) as an enzyme at 60 °C (Scheme 2b). The kinetic hydrolyses 
were performed on gram-scale (1.0 g of substrate) after optimizing the reaction conditions for each 
starting material. The enantioselective ring-cleavage of the (3R*,4S*)-β-lactams (R=H) in tert-butylmethyl 
ether (TBME) (with 0.5 eq. of water) yielded, after 18 h, the (3S,4R)-β-lactam (>99% ee, 48% yield) and 
(2R,3S)-3-phenylisoserine (98% ee, 48% yield). These two compounds were also formed with high 
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Another strategy to produce the (2R,3S)-3-phenylisoserine involved the enantioselective
ring-cleavage of (3R*,4S*)-β-lactam (R=H) and its 3-acetoxy derivative (R=Ac) using CAL-B
(lipase B from Candida antarctica produced by the submerged fermentation of a genetically modified
Aspergillus oryzae and absorbed on a macroporous resin) as an enzyme at 60 ˝C (Scheme 2b). The kinetic
hydrolyses were performed on gram-scale (1.0 g of substrate) after optimizing the reaction conditions
for each starting material. The enantioselective ring-cleavage of the (3R*,4S*)-β-lactams (R=H)
in tert-butylmethyl ether (TBME) (with 0.5 eq. of water) yielded, after 18 h, the (3S,4R)-β-lactam
(>99% ee, 48% yield) and (2R,3S)-3-phenylisoserine (98% ee, 48% yield). These two compounds were
also formed with high enantioselectivity (>98% ee) and good yields (43% and 49%, respectively)
when the reaction was performed with the (3R*,4S*)-3-acetoxy-β-lactam (R=Ac). In this case, the
solvent was DIPE (1.0 eq. H2O) and, after 50 h, the starting material was 100% converted into the
enantiopure products (>98% ee) [10].
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observed with different commercial lipases (CAL-B and Rhizopus delemar lipase, among the others),
and provided the (S)-ester and (R)-alcohol with ee ranging from 80% to 97%. Then, these two
compounds were not separated, and the mixture was subjected to mesylation reaction (conversion
of the (R)-alcohol into its mesyl derivative), followed by treatment with potassium acetate to
exclusively yield the (S)-ester. Hydrolysis of this compound furnished the desired product
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2.3. Pregabalin and Analogues
Pregabalin ((S)-3-(aminomethyl)-5-methylhexanoic acid, trade name Lyricar) is a drug used
in anticonvulsant therapy. Pregabalin and its analogues were obtained by hydrolysis of γ-nitro esters,
followed by hydrogenation of the nitro group on Raney nickel. Hydrolysis of the γ-nitro esters can be
effectively catalyzed by lipase Novozym 435, as seen in Scheme 4a, affording (S)-γ-nitro acids
with moderate conversion (18%–24%) and ee ranging between 87% and 94% [13]. Additionally,
2-carboxyethyl-3-cyano-5-methylhexanoic acid ethyl ester (CNDE) was enantioselectively hydrolyzed
as the key step in the preparation of Pregabalin (Scheme 4b). This biotransformation was achieved
by using Thermomyces lanuginosus lipase (TLL), the enzyme contained in commercial Lipolaser
and Lipozyme TL IMr. Recombinant lipase from T. lanuginosus DSM 10635 showed excellent
(S)-enantioselectivity to CNDE (E > 200), but with low catalytic activity. The enzyme was evolved by
protein engineering, allowing the preparation of (3S)-2-carboxyethyl-3-cyano-5-methylhexanoic acid
with 42% conversion and 98% ee, starting from 255 g/L of substrate [14].
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2.4. Prosimpal, Piperoxan, Dibozane and Doxazosin
The drugs (S)-Prosimpal, (S)-Piperoxan and (S,S)-Dibozane are α-adrenergic receptor antagonists,
and (S)-Doxazosin is a drug used in the treatment of hypertension. All (S)-isomers are more effective
than the corresponding (R)-isomers. The aforementioned drugs were synthesized by hydrolytic
kinetic resolution of the racemic intermediate methyl-1,4-benzodioxan-2-carboxylate in the presence
of lipase from whole cells of wild species of Arthrobacter (ABL), as seen in Scheme 5. The reactions
were performed in two different conditions: (i) 0.1 M phosphate buffer with 20% DIPE as a co-solvent
and (ii) 0.1 M phosphate buffer with 20% of n-butanol as a co-solvent. In the first reaction condition,
after 2 h of reaction, the corresponding (S)-carboxylic acid (79% ee) and the (R)-methyl ester (>99% ee)
were obtained with c 55% and E-value of 33. In the second reaction condition, after 4 h, (S)-carboxylic
acid (>99% ee) and (R)-methyl ester (73% ee) were obtained with c 42% and E > 200. The syntheses of
the pharmaceuticals (S)-Prosimpal, (S)-Piperoxan and (S,S)-Dibozane were performed by using the
(R)-methyl ester (>99% ee) obtained from the first reaction condition, while the (S)-carboxylic acid
(>99% ee) obtained in the second condition was used in the synthesis of (S)-Doxazosin [15].
2.5. Key Intermediate of Ezetimibe
Ezetimibe is a drug used in the reduction of cholesterol and blood lipids. The synthesis of
this drug requires the enantiopure 3-[5-(4-fluorophenyl)-5(S)-hydroxypentanoyl]-4(S)-4-phenyl-1,
3-oxazolidin-2-one ((S)-FOP alcohol) as a key intermediate. Kinetic resolution of the diastereoisomeric
mixture of FOP acetates was assessed using several commercial lipases; the most efficient lipase
was from Candida rugosa (CRL) and the best reaction conditions were buffer solution (pH 7.0)
containing 30% of DIPE as a co-solvent, at 40 ˝C, and an enzyme:substrate (w/w) ratio of 2.5:1.
In such conditions, after reaching 50% conversion, it was possible to obtain (S)-FOP acetate with
diastereomeric excess (de) 98.5% (Scheme 6). The same results were obtained when the method was
applied to scale-up, starting from 1 g of the diastereoisomeric mixture of FOP acetates [16].
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2.6. Key Intermediate of Hepatitis C Virus Protease Inhibitor 
The chiral compound trans-alkyl (1R,2S)-1-(tert-butoxycarbonylamino)-2-vinylcyclopropanecarboxylate 
is an important intermediate for the synthesis of certain Hepatitis C virus protease inhibitors. Initially, 
rac-dialkyl 2-vinyl-1,1-cyclopropanedicarboxylate was submitted to a kinetic resolution in the 
presence of various hydrolytic enzymes including lipases (lipase OF from Candida rugosa; lipase from 
Mucor miehei; lipase OF from C. rugosa (formerly C. cylindracea); and lipase N from Rhizopus niveus). 
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a substrate concentration of 10 mg/mL. Under these conditions, a conversion of 49% and an E-value
of 174.2 were reached (Scheme 8) [18].
The same biotransformation was improved by using nanoparticles as additives for the
encapsulation of the enzyme via the sol–gel method. The encapsulated lipase showed outstanding
enantioselectivity, with an E-value ranging from 265 to 371 and >98% ee depending on the sol–gel
encapsulation process employed [19].
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vinyl ester was obtained by enzymatic hydrolysis using a lipase from Aspergillus terreus immobilized
on modified alginate and cyclodextrin hollow spheres [21]. Under optimized conditions (enzyme
immobilized on Alg-g-PEG/α-CD hollow spheres used in acetone/water 80/20, pH 7.4, at 30 ˝C),
the biotransformation was enantioselective (E-value of 129), furnishing (R)-Ketoprofen (96% ee at
46% conversion). Under the same conditions, free A. terreus lipase gave only 16% conversion with
low enantioselectivity (E-value of 11.4), as seen in Scheme 10a and Table 1. Notably, immobilized
A. terreus lipase was continuously used up to 20 cycles with minimal loss of activity, whereas the free
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A new approach to resolve racemic Ketoprofen vinyl ester was developed after comparison
of the performances of different lipases (from Mucor javanicus, Rhizomucor miehei, Candida rugosa
and Pseudomonas cepacia) employed both as free enzymes or immobilized in micro-emulsion-based
organogels (MBGs) [22]. The reactions were conducted in the presence of DIPE at 30 ˝C. The
bioconversion with free lipases generally provided low conversions (maximum 12%) compared with
the immobilized lipases (maximum yield 49%). Immobilized Mucor javanicus lipase (MJL) exhibited
the highest enantioselectivity (E > 200), whereas immobilized Rhizomucor miehei lipase (RML)
displayed a moderate E-value (35), but proved to be tolerant to various organic solvents such as DIPE,
TBME, tetrahydrofuran (THF), 2-MeTHF, 1,4-dioxane, acetone and MeCN. Moreover, immobilized
RML was very thermostable up to 50 ˝C. It is noteworthy that immobilized RML and MJL showed
high activity over 30 cycles and maintained the same initial enantioselectivity. RML immobilized
in micro-emulsion-based organogels was employed for a 5-g-scale kinetic resolution of Ketoprofen
vinyl ester, furnishing the desired product (91% ee) in 47% yield after 72 h (Scheme 10b and Table 1).
The authors highlight the advantages of biotransformations catalyzed by immobilized enzymes in
the form of MBGs; these advantages include an improved enzymatic efficiency (conversion and
enantioselectivity), excellent reusability, low enzyme loading, and enhanced resistance to organic
solvents. Long-term resistance to high concentrations of organic solvents is a crucial feature in
lipase-catalyzed reactions, especially when working with poorly water-soluble substrates. Studies
on the effect of interfacial composition on lipase activity in two-liquid phase systems revealed that
substrate inaccessibility is a major reason for the low activity of lipase in the absence of organic
solvents [23].
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Table 1. Enzymes and conditions used on the kinetic enzymatic hydrolysis of rac-Ketoprofen vinyl
ester by methods a and b.
Method Enzyme Conditions Reference
a lipase from A. terreus immobilized onAlg-g-PEG/α-CD, hollow spheres
acetone/water (80/20, v/v),
pH 7.4, 30 ˝C, 4 days [21]
b MJL MBGs or RML MBGs DIPE, 30 ˝C, 72 h [22]
2.10. Dihydropyridine Derivatives
The 1,4-Dihydropyridines (1,4-DHPs) are recognized as pharmacophores widely used in clinics
for the treatment of cardiovascular diseases. A series of racemic 1,4-DHPs were prepared through
several chemical steps including a multicomponent Hantzsch process and a Vilsmeir-Haack reaction.
These 1,4-DHPs were subjected to enzymatic kinetic resolution via hydrolysis in the presence of
lipases in water saturated with organic solvent [24]. Reactions were carried out until conversions next
to 50% and several lipases (such as from Candida antarctica A (CAL-A, NZL-101), porcine pancreatic
lipase (PPL), from C. antarctica B (CAL-B, Novozym 435) and from C. rugosa (CRL, type VII)) were
assayed. The best results were obtained in the presence of CRL or CAL-B depending on the aryl group
and the organic solvent. For reaction systems containing CRL and EtOAc as a solvent, the highest
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enantioselectivity values (E) were obtained with 1,4-DHPs containing aryl groups as 2-NO2–C6H4,
naphtyl and 2-Cl–5-NO2–C6H3 with E-values of 103, 170 and >200, respectively. The ee values of the
remaining ester were in the range of 84% to >99% while the ee of the carboxylic acid product ranged
from 94% to 98%. It is noteworthy that some of the carboxylic acid products had the enantiomeric
excess increased by crystallization. Applying this methodology, ee values of the carboxylic acid
products containing aryl groups (i.e., 3-NO2–C6H4; Ph; and 4-NO2–C6H4) were enhanced from 88%
to 97%; 60% to 92%; and 69% to 95%, respectively. In the presence of CAL-B and EtOAc as a solvent,
the best result was obtained with a 1,4-DHP-containing aryl group such as 3-CH3O–C6H4 with an
E-value of 63, c 34%, 49% ee to the remaining ester and 95% ee to the carboxylic acid product. In order
to obtain the remaining substrate with high ee, hydrolysis of 1,4-DHPs containing aryl groups such
as 4-Br–C6H4 and 3-CH3O–C6H4 was carried out with CAL-B and TBME as a solvent affording 57%
and 54% molar conversion, respectively. In this case, remaining substrates (aryl = 4-Br–C6H4) and
(aryl = 3-CH3O–C6H4) were obtained with high ee, 97% and 94%, respectively (Scheme 11).
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stereoselective acylation of alcohols when the reaction is performed under low water activity 
conditions. This opportunity can be exploited for achieving the highly regio- or stereoselective 
preparation of esters with pharmaceutical relevance under mild and controlled conditions. Examples 
span from structurally simple drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs), to 
multifunctional complex molecules, such as immunosuppressive agents (i.e., Rapamycin or 
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3. Esterification Approach
As known to most of the researchers working in this area, lipases can efficiently catalyze
the stereoselective acylation of alcohols when the reaction is performed under low water activity
conditions. This opportunity can be exploited for achieving the highly regio- or stereoselective
preparation of esters with pharmaceutical relevance under mild and controlled conditions. Examples
span from structurally simple drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs), to
multifunctional complex molecules, such as immunosuppressive agents (i.e., Rapamycin or Pimecrolimus),
where regioselectivity is a major issue.
3.1. Rapamycin
A brilliant example of regioselectivity observed in lipase-catalyzed acylation is the synthesis
of the proline analogue of Rapamycin dihydroxyesters, where the chemoenzymatic approach
allowed the preparation of the desired molecule in only two steps [25]. Identification of a suitable
activated ester of the 2,2-bis(hydroxymethyl) propionic acid side chain was crucial for performing
the lipase-catalyzed acylation; vinyl esters provided the highest activity and the best yield, allowing
for preparative synthesis. Immobilized lipase PS-C “Amano” II was the best biocatalyst, displaying
optimal activity in anhydrous TBME (Scheme 12).
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3.3. Loxoprofen
A considerable number of biocatalytic routes have been developed so far for the production of
(S)-profens; nevertheless, more efficient and sustainable processes are needed due to the commercial
importance of these drugs. Loxoprofen, an (S)-2-(4-(R)-2-oxo–cyclopentylmethyl)phenyl propionic
acid, is a NSAI drug belonging to the group of propionic acid derivatives with anti-inflammatory,
analgesic and antipyretic activities. In fact, Loxoprofen is a pro-drug because its active form is
the corresponding trans-alcohol metabolite. The preparation of Loxoprofen involved the enzymatic
kinetic resolution of the racemic alcohol 2-(p-{[(p-methoxy phenyl)methoxy]methyl}phenyl)propanol
via transesterification reaction in the presence of lipase from Burkholderia cepacia (lipase-PS), molecular
sieves 4 Å, in DIPE as a solvent and vinyl acetate as an acyl donor (Scheme 14). After 12 h, it was
possible to obtain the corresponding (S)-acetate in 98% enantiomeric excess (ee) and the (R)-alcohol
in 94% ee. The synthesis of Loxoprofen followed with (S)-acetate having the desired configuration of
the drug [28].
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racemic drug was performed in flow-reactor, which is considered an interesting approach for the 
development of the lipase-catalyzed preparation of enantiopure molecules [30,31]. It is also worth 
mentioning that these automated systems help continuous bioprocesses, provide easy reaction 
optimization (including parameters such as residence time), and allow for multistep reactions and 
inline recovery and purification of the products [32,33]. Thus, as a proof of concept, direct 
esterification in organic solvent using commercial enzyme (Novozym 435) [30] and the whole 
microorganism (A. oryzae, MIM) [31] were compared with the classical batch method. The protocol 
inflow reactor showed a significant reduction of the reaction time (from 6 h to 15–60 min) and yielded 
both the (S)-Flurbiprofen and (R)-Flurbiprofen butyl ester with ≥90% ee (chemical purity >98%) by 
modulating the reaction conditions (temperature and residence time), as seen in Scheme 15. 
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3.5. Ibuprofen
Ibuprofen is another NSAI agent with anti-inflammatory activity and wide commercial interest.
A racemic mixture of Ibuprofen was resolved in the presence of commercially available lipases OF
and CRL type VII from Candida rugosa immobilized onto magnetic beads. Immobilization was
performed via a glutaraldehyde or N-3-(3-dimethylaminopropyl)-N’-ethylcarbodiimide (EDC)/
N-hydroxysulfosuccinimide sodium salt (sulfo-NHS) cross-linking reaction. The immobilized enzymes
were evaluated for the preparation of Ibuprofen propyl ester. All reactions provided the (S)-ester as
the product, and the best result (E-value of 19, 83% ee and c 42%) was achieved in the presence of
the immobilized lipase from C. rugosa OF, as well as in the presence of additives such as Na2SO4 and
molecular sieves 4 Å (Scheme 16). The study of reuse demonstrated continued stability and catalytic
activity after five reaction cycles [34].
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3.6. Ketorolac 
Ketorolac (rac-5-benzoyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid) is a potent 
NSAI drug belonging to the class of the heterocyclic acetic acid derivatives, and it is widely used as 
an analgesic. The microwave (MW)-assisted kinetic resolution of this compound was investigated 
using different immobilized lipases, such as Novozym 435, Lipozyme TL IM, Lipozyme RM IM, 
lipase Amano AS, and lipase AYS Amano [35]. Among them, Novozym 435 catalyzed the 
enantioselective acylation of rac-Ketorolac in 3 h, at 50 °C and 300 rpm, with c 50% and high ee values 
(>99%) for both the (R)-ester and remaining (S)-acid (Scheme 17). In addition, the reaction was found 
to follow the Ping-Pong bi-bi mechanism, and to be inhibited by n-octanol. 
 
Scheme 17. Enzymatic kinetic resolution of rac-Ketorolac, a potent nonsteroidal anti-inflammatory drug [35]. 
3.7. Chloramphenicol and Thiamphenicol 
Another pharmacological field where the use of lipases has been particularly active in the recent 
past is the elaboration of antibiotics. The compound (1R,2R)-(−)-Chloramphenicol is an effective 
antibiotic against a wide range of Gram-positive and Gram-negative bacteria. This drug can be 
administered in capsule or liquid forms, and it has a bitter taste. One way to overcome this problem 
is to use esters of chloramphenicol, which are more palatable. Several chloramphenicol esters were 
prepared regioselectively in the presence of lipases. Then (−)-Chloramphenicol was subjected to 
esterification reaction in the presence of a series of vinyl esters containing alkyl chains of varying 
sizes (one to 15 carbon atoms), as well as in the presence of a number of lipases. The more efficient 
lipases were from Candida antarctica B (CAL-B, Novozym 435) and two different preparations from 
Pseudomonas cepacia, one from Amano (PSL-C Amano, also known as Burkholderia cepacia) and another 
from Sigma-Aldrich® (PSLC-I). With CAL-B, the best reaction conditions were in the presence of 
MeCN as a solvent at 20 °C; with PSL-C I and PSL-C Amano, the ideal solvent was 1,4-dioxane at 30 °C. 
Generally, monoesters of chloramphenicol acylated on the primary hydroxyl were obtained with c >99% 
(isolated yields between 75% and 91%) for reaction times between 3 and 10 h (Scheme 18 and Table 2). It 
is noteworthy that the study of the reuse of CAL-B in esterification with vinyl palmitate was 
performed. As a result, it was observed that after 3 h of reaction, there was complete conversion 
during 10 cycles of reuse of the enzyme [36]. The same strategy was used on the synthesis of 
Thiamphenicol esters from (1R,2R)-(−)-Thiamphenicol, an antibiotic analogue of chloramphenicol 
with veterinary applications. The esters were regioselectively prepared via acylation reaction in the 
presence of lipases and vinyl esters with variable lengths. The most effective lipase was CAL-B in MeCN, 
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NSAI drug belonging to the class of the heterocyclic acetic acid derivatives, and it is widely used as an
analgesic. The microwave (MW)-assisted kinetic resolution of this compound was investigated using
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Amano AS, and lipase AYS Amano [35]. Among them, Novozym 435 catalyzed the enantioselective
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past is the elaboration of antibiotics. The compound (1R,2R)-(´)-Chloramphenicol is an effective
antibiotic against a wide range of Gram-positive and Gram-negative bacteria. This drug can be
administered in capsule or liquid forms, and it has a bitter taste. One way to overcome this problem
is to use esters of chloramphenicol, which are more palatable. Several chloramphenicol esters were
prepared regioselectively in the presence of lipases. Then (´)-Chloramphenicol was subjected to
esterification reaction in the presence of a series of vinyl esters containing alkyl chains of varying
sizes (one to 15 carbon atoms), as well as in the presence of a number of lipases. The more efficient
lipases were from Candida antarctica B (CAL-B, Novozym 435) and two different preparations from
Pseudomonas cepacia, one from Amano (PSL-C Amano, also known as Burkholderia cepacia) and another
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from Sigma-Aldrichr (PSLC-I). With CAL-B, the best reaction conditions were in the presence of
MeCN as a solvent at 20 ˝C; with PSL-C I and PSL-C Amano, the ideal solvent was 1,4-dioxane at
30 ˝C. Generally, monoesters of chloramphenicol acylated on the primary hydroxyl were obtained
with c >99% (isolated yields between 75% and 91%) for reaction times between 3 and 10 h (Scheme 18
and Table 2). It is noteworthy that the study of the reuse of CAL-B in esterification with vinyl
palmitate was performed. As a result, it was observed that after 3 h of reaction, there was complete
conversion during 10 cycles of reuse of the enzyme [36]. The same strategy was used on the synthesis
of Thiamphenicol esters from (1R,2R)-(´)-Thiamphenicol, an antibiotic analogue of chloramphenicol
with veterinary applications. The esters were regioselectively prepared via acylation reaction in the
presence of lipases and vinyl esters with variable lengths. The most effective lipase was CAL-B in
MeCN, at 20 ˝C. Thiamphenicol esters (acylated at the primary hydroxyl group) were regioselectively
produced with c >99% and isolated yields between 94% and 98%, as seen in Scheme 18 and Table 2.
A study of the reuse of lipase from C. antarctica type B (CAL-B, Novozym 435) was conducted for the
acylation of (´)-Thiamphenicol with vinyl decanoate. The corresponding 3’-monoester was obtained
in 96% yield and the enzyme was reused five times without any loss of the activity [37].
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1,4-dioxane, 30 °C 75–91 36 
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3.8. Key Intermediates of Modified Cephalosporins 
Some modified Cephalosporins and the anti-inflammatory agent N-[(9H-fluoren-9-
ylethoxy)carbonyl]-L-leucine tert-butyl ester have a chiral fragment resulting from the incorporation 
of 1-(9H-fluoren-9-yl)ethanol in their structures. The first chemoenzymatic synthesis of this chiral 
fragment was performed in the presence of lipases. Initially, racemic 1-(9H-fluoren-9-yl)ethanol was 
chemically obtained, and then it was submitted to a kinetic resolution via acetylation reaction. Fifteen 
commercial lipases were evaluated by studying parameters considered important in the kinetic 
resolution process, such as the substrate/lipase ratio and solvent. The best results were obtained in 
the kinetic resolution with an enzymatic aggregate of lipase from Candida antarctica A (CAL-A CLEA, 
Amano lipase A). It is worth noting that depending on the reaction conditions, both (S)- and (R)-1-
(9H-fluoren-9-yl) ethanol (obtained from the hydrolysis of the corresponding acetate) could be 
prepared with >99% ee. In the first condition (i), after 24 h of reaction, with an enzyme/substrate (w/w) 
ratio of 10% and TBME as a solvent, it was possible to obtain the (S)-alcohol and (R)-acetate with 
enantiomeric excess (ee) >99% and 93%, respectively (E-value of 145, c 52%), as seen in Scheme 19. In 
the second condition (ii), a dramatic decrease in the reaction rate was observed with a decreasing 
enzyme/substrate ratio to 1.25%. After nine days, the (S)-alcohol (68% ee) and (R)-acetate (>99% ee) 
were obtained with c 41% and E > 200 [38]. 
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the synthesis of modified Cephalosporins and the anti-inflammatory agent N-[(9H-fluoren-9-
ylethoxy)carbonyl]-L-leucine tert-butyl ester [38]. 
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Scheme 19. Kinetic enzymatic acylation of rac-1-(9H-fluoren-9-yl)ethanol, affording intermediates in
the synthesis of modified Cephalosporins and the anti-inflammatory agent N-[(9H-fluoren-9-
ylethoxy)carbonyl]-L-leucine tert-butyl ester [38].
3.9. Key Intermediate of Duloxetin
BASF AG patented the chemoenzymatic synthesis of (S)-3-(methylamino)-1-(thiophen-2-
yl)propan-1-ol, a key intermediate in the synthesis of the serotonin-norepinephrine reuptake inhibitor
Duloxetine ((+)-(S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine oxalate) [39]. Chemical
reduction of 3-chloro-1-(thiophen-2-yl)propan-1-one gives access to the corresponding rac-alcohol,
which was enantioselectively acylated with succinic anhydride using lipase from Burkholderia plantarii or
from Pseudomonas sp., furnishing the corresponding (R)-semiester, leaving the unreacted (S)-alcohol.
The reaction between the (S)-alcohol and methylamine afforded the enantiomerically pure desired
product (Scheme 20).
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3.10. Nebracetam 
Nebracetam, a nootropic drug from the racetam family, is used as an anti-depressant (M1 
acetylcholine receptor agonist). The first asymmetric synthesis of (S)-Nebracetam was efficiently 
conducted from the intermediate (5S)-1-benzyl-5-hydroxy-1,5-dihydropyrrol-2-one which was 
obtained by kinetic resolution of the racemic hydroxylactam (1-benzyl-5-hydroxy-1,5-dihydropyrrol-2-one). 
The acetylation was performed in the presence of lipase from Burkholderia cepacia (lipase PS-D), vinyl 
acetate as an acyl donor, 1,4-dioxane as the organic solvent at room temperature and 48 h of reaction 
(Scheme 21). Accordingly, the corresponding (R)-acetate and (S)-alcohol were obtained with excellent 
enantioselectivity and conversion (>99% ee, c 49% and E > 200). Then, after several chemical steps, the 
(5S)-alcohol was converted into (S)-Nebracetam [40]. 
 
Scheme 21. Kinetic resolution of the racemic hydroxylactam to produce the (5S)-1-benzyl-5-hydroxy-
1,5-dihydropyrrol-2-one used in the synthesis of the drug (S)-Nebracetam [40]. 
3.11. Naphthofurandione derivative 
The naphthofurandione (S)-5-hydroxy-2-(1-hydroxyethyl)naphtho[2,3-b]furan-4,9-dione, with 
antitumor activity, is a secondary metabolite isolated from the bark of Tabebuia impetiginosa 
(Bignoniaceae). Naphthofurandione was prepared in racemic form through several chemical steps 
from commercially available 1,5-dihydroxynaphthalene. Then, the rac-naphthofurandione was 
subjected to enzymatic kinetic resolution via acetylation reaction (Scheme 22). Among the evaluated 
lipases, Pseudomonas cepacia, (PSL-CI, 3 h of reaction) and lipase from Candida antarctica B, (Novozym 435, 
2 h of reaction) were the most efficient. The best reaction conditions were vinyl acetate as the acyl 
donor, THF as the solvent, 250 rpm, at 30 °C, leading to (S)-alcohol and the corresponding (R)-acetate 
with 99% ee for both and E > 200 [41]. 
 
Scheme 22. Synthesis of the naphthofurandione (S)-5-hydroxy-2-(1-hydroxyethyl)naphtho[2,3-b]furan-
4,9-dione via kinetic enzymatic acylation of the corresponding racemic alcohol [41]. 
Scheme 20. Kinetic enzymatic acylation of the rac-3-chloro-1-(thiophen-2-yl)propan-1-ol used in the
chemoenzymatic synthesis of (S)-3-(methylamino)-1-(thiophen-2-yl)propan-1-ol, a key intermediate
in the synthesis of the serotonin-norepinephrine reuptake inhibitor Duloxetine [39].
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acetate as an acyl donor, 1,4-dioxane as the organic solvent at room temperature and 48 h of reaction
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3.11. Naphthofurandione Derivative
The naphthofurandione (S)-5-hydroxy-2-(1-hydroxyethyl)naphtho[2,3-b]furan-4,9-dione, with
antitumor activity, is a secondary metabolite isolated from the bark of Tabebuia impetiginosa
(Bignoniaceae). Naphthofurandione was prepared in racemic form through several chemical steps
from commercially available 1,5-dihydroxynaphthalene. Then, the rac-naphthofurandione was
subjected to enzymatic kinetic resolution via acetylation reaction (Scheme 22). Among the evaluated
lipases, Pseudomonas cepacia, (PSL-CI, 3 h of reaction) and lipase from Candida antarctica B, (Novozym
435, 2 h of reaction) were the most efficient. The best reaction conditions were vinyl acetate as the acyl
donor, THF as the solvent, 250 rpm, at 30 ˝C, leading to (S)-alcohol and the corresponding (R)-acetate
with 99% ee for both and E > 200 [41].
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Scheme 22. Synthesis of the naphthofurandione (S)-5-hydroxy-2-(1-hydroxyethyl)naphtho[2,3-b]
furan-4,9-dione via kinetic enzymatic acylation of the corresponding racemic alcohol [41].
3.12. GABOB and Carnitine
The compounds (R)-γ-Amino-β-hydroxybutyric acid (GABOB) and (R)-carnitine are two important
bioactive molecules that play an important role in mammalian systems. The key step of the
chemoenzymatic syntheses of these two compounds involved the lipase-mediated resolution of
the racemic 3-hydroxy-4-tosyloxybutanenitrile in organic solvents (Scheme 23). Lipases (free or
immobilized forms) from Pseudomonas cepacia (PS), P. fluorescens (AK), Candida rugosa (CRL AYS),
C. antarctica (CAL-B) and Mucor miehei (Lipozyme) were used as biocatalysts, and yielded the
(S)-alcohol and (R)-acetate in high enantioselectivity (>99% ee). After some chemical transformations,
the (R)-acetate isomer was converted into (R)-GABOB and (R)-carnitine [42].
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Scheme 23. Kinetic resolution of the racemic 3-hydroxy-4-tosyloxybutanenitrile to produce (R)-GABOB 
and (R)-carnitine [42]. 
3.13. Quinolone Derivatives 
The quinolone 2-[2-hydroxy-3-(4-phenylpiperazin-1-yl)propyl]-1H-pyrrolo[3,4-b]quinolin-3(2H)-one 
was chemically synthesized and subsequently subjected to enzymatic kinetic resolution via acylation 
reaction (Scheme 24). The best results were obtained using lipase from Candida antarctica B (CAL-B), 
and vinyl acetate as a both solvent and acyl donor at room temperature. After 48 h of reaction, it was 
possible to obtain the corresponding (R)-acetate in 36% yield and 96% ee; (S)-quinolone was obtained 
in 41% yield and 98% ee, c 50% and E > 200. The (S)-quinolone as well as the corresponding (R)-acetate 
showed significant cytotoxic activity against human neuroblastoma tumor cells (SK-N-SH) and lung cells 
(A549) compared to the control doxorubicin [43]. 
 
Scheme 24. Kinetic enzymatic acylation of the racemic quinolone 2-[2-hydroxy-3-(4-phenylpiperazin-1-
yl)propyl]-1H-pyrrolo[3,4-b]quinolin-3(2H)-one [43]. 
3.14. Key Intermediate of Mevinic Acid Analogues 
Analogues of mevinic acid can be obtained from (S)-1-(1-naphthyl)ethanol. A racemic mixture 
of this compound was resolved in the presence of lipases using microwave. Several parameters were 
studied and the best reaction conditions were Novozym 435 as a biocatalyst, vinyl acetate as an acyl 
donor, n-heptane as a solvent, a stirring speed of 400 rpm, temperature at 60 °C and 30 mg of enzyme 
loading. In such conditions, after 3 h of reaction, the (S)-1-(1-naphthyl)ethanol was obtained with  
c 48%, 90.0% ee and E > 200 (Scheme 25). The study of reuse of the enzyme was performed with a 
slight reduction of conversion from 48% to 45% after being used three times. It is noteworthy that the 
results from the conventional heating (c 39%, 64% ee and E-value of 164 after 5 h of reaction) were 
inferior to those obtained under microwave conditions [44]. 
  
Scheme 23. Kinetic resolution of the racemic 3-hydroxy-4-tosyloxybutanenitrile to produce
(R)-GABOB and (R)-carnitine [42].
3.13. Quinolone Derivatives
The quinolone 2-[2-hydroxy-3-(4-phenylpiperazin-1-yl)propyl]-1H-pyrrolo[3,4-b]quinolin-3(2H)-
one was chemically synthesized and subsequently subjected to enzymatic kinetic resolution via
acylation reaction (Scheme 24). The best results were obtained using lipase from Candida antarctica
B (CAL-B), and vinyl acetate as a both solvent and acyl donor at room temperature. After 48 h
of reaction, it was possible to obtain the corresponding (R)-acetate in 36% yield and 96% ee;
(S)-quinolone was obtained in 41% yield and 98% ee, c 50% and E > 200. The (S)-quinolone as well
as the corresponding (R)-acetate showed significant cytotoxic activity against human neuroblastoma
tumor cells (SK-N-SH) and lung cells (A549) compared to the control doxorubicin [43].
29696
Int. J. Mol. Sci. 2015, 16, 29682–29716
Int. J. Mol. Sci. 2015, 16, page–page 
14 
3.12. GABOB and carnitine 
The compounds (R)-γ-Amino-β-hydroxybutyric acid (GABOB) and (R)-carnitine are two 
important bioactive molecules that play an important role in mammalian systems. The key step of 
the chemoenzymatic syntheses of these two compounds involved the lipase-mediated resolution of 
the racemic 3-hydroxy-4-tosyloxybutanenitrile in organic solvents (Scheme 23). Lipases (free or 
immobilized forms) from Pseudomonas cepacia (PS), P. fluorescens (AK), Candida rugosa (CRL AYS), C. 
antarctica (CAL-B) and Mucor miehei (Lipozyme) were used as biocatalysts, and yielded the (S)-alcohol 
and (R)-acetate in high enantioselectivity (>99% ee). After some chemical transformations, the (R)-acetate 
isomer was converted into (R)-GABOB and (R)-carnitine [42]. 
 
Scheme 23. Kinetic resolution of the racemic 3-hydroxy-4-tosyloxybutanenitrile to produce (R)-GABOB 
and (R)-carnitine [42]. 
3.13. Quinolone Derivatives 
The quinolone 2-[2-hydroxy-3-(4-phenylpiperazin-1-yl)propyl]-1H-pyrrolo[3,4-b]quinolin-3(2H)-one 
was chemically synthesized and subsequently subjected to enzymatic kinetic resolution via acylation 
reaction (Scheme 24). The best results were obtained using lipase from Candida antarctica B (CAL-B), 
and vinyl acetate as a both solvent and acyl donor at room temperature. After 48 h of reaction, it was 
possible to obtain the corresponding (R)-acetate in 36% yield and 96% ee; (S)-quinolone was obtained 
in 41% yield and 98% ee, c 50% and E > 200. The (S)-quinolone as well as the corresponding (R)-acetate 
showed significant cytotoxic activity against human neuroblastoma tumor cells (SK-N-SH) and lung cells 
(A549) compared to the control doxorubicin [43]. 
 
Scheme 24. Kinetic enzymatic acylation of the racemic quinolone 2-[2-hydroxy-3-(4-phenylpiperazin-1-
yl)propyl]-1H-pyrrolo[3,4-b]quinolin-3(2H)-one [43]. 
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studied and the best reaction conditions were Novozym 435 as a biocatalyst, vinyl acetate as an acyl 
donor, n-heptane as a solvent, a stirring speed of 400 rpm, temperature at 60 °C and 30 mg of enzyme 
loading. In such conditions, after 3 h of reaction, the (S)-1-(1-naphthyl)ethanol was obtained with  
c 48%, 90.0% ee and E > 200 (Scheme 25). The study of reuse of the enzyme was performed with a 
slight reduction of conversion from 48% to 45% after being used three times. It is noteworthy that the 
results from the conventional heating (c 39%, 64% ee and E-value of 164 after 5 h of reaction) were 
inferior to those obtained under microwave conditions [44]. 
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Compounds (+)- and (´)-1-(5,5-diphenyltetrahydrofuran-3-yl)-N,N-dimethylmethanamine
showed neuroprotective, antidepressant and antiepileptic activities. Such compounds were prepared
by chemoenzymatic synthesis starting from 5,5-diphenyltetrahydrofuran-2(3H)-one. The key step
for introducing chirality in the target molecule was the desymmetrization of the intermediate
3-(hydroxymethyl)-1,1-diphenylbutane-1,4-diol, using vinyl acetate as an acylating agent in the presence
of lipase from Burkholderia cepacia (Amano lipase PS30), to obtain the (+)-4-hydroxy-2-(hydroxymethyl)-4,
4-diphenylbutyl acetate (Scheme 26). The latter compound was subjected to two different synthetic
routes. The first (a) involved a sequence of reactions including tosylation, and hydrolysis and reaction
with 2,6-lutidine in the presence of trifluoromethane sulfonic anhydride to afford the (+)
1-(5,5-diphenyltetrahydrofuran-3-yl)-N,N-dimethylmethanamine. In the second synthetic route (b),
the intermediate (+)-4-hydroxy-2-(hydroxymethyl)-4,4-diphenylbutyl acetate was subjected to a step of
protecting one of the hydroxyl groups with tert-butyldimethylsilyl chlroride (TBSCl), followed by
hydrolysis in the presence of LiOH/H2O, tosylation reaction and deprotection with tetrabutylammonium
fluoride (TBAF). Finally, a reaction with 2,6-lutidine in the presence of trifluoroacetic sulfonic
anydride led to the (´)-1-(5,5-diphenyltetrahydrofuran-3-yl)-N,N-dimethylmethanamine. It should
be mentioned that the absolute configurations of the products were not reported by the authors [45].
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Scheme 27. Kinetic enzymatic acylation of racemic trans- and cis-diastereoisomers of  
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Table 3. Efficient lipases for the kinetic enzymatic acylation of racemic trans- and cis-diastereoisomers 
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carboxybenzyl-2-amino-1,3-propanediol (Cbz-serinol) via acetylation reaction in THF mediated by 
crude pig pancreatic lipase (PPL, L3126, type II, Steapsin) (i) or purified PPL (L0382, type VI-S) (ii) 
was reported [47]. When the reaction was carried out in vinyl acetate as both a solvent and acyl donor, 
in the presence of crude PPL (i), only the (2R)-monoacetate was formed in 98% ee. On the other hand, 
only the (2S)-monoacetate (100% ee) was formed when purified PPL (ii) catalyzed the 
desymmetrization (Scheme 28). 
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of lipase from Rhizomucor miehei (RML). Ethyl acetamidocianoacetate was alkylated in the presence 
of various alkyl halides in phase transfer catalysis (PTC), followed by acidic hydrolysis, esterification 
and N-acetylation leading to N-acetyl-phenylalanine methyl and allyl esters derivatives. These 
derivatives were submitted to an enzymatic kinetic resolution via interesterification reaction. After 
screening with various commercial lipases, it was found that only RML was able to promote the 
kinetic resolution (Scheme 29). Several parameters were studied and the best reaction conditions were 
obtained in the presence of butyl butyrate as an interesterification agent, with an enzyme:substrate 
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3.18. N-Acetyl Phenylalanine and Analogues
Phenylalanine and analogues are important building blocks in the preparation of complex
structures of interest to the medicinal chemistry area. N-Acetyl phenylalanine and a series of
analogues were obtained in enantiomeri ally pure form by interesterification reaction in the presence
of lipas from Rhizomucor miehei (RML). Ethyl acetamidocianoacetate was alkylated in the presence of
various alkyl halides in phase transfer catalysis (PTC), followed by acidic hydrolysis, esterification
and N-acetylation leading to N-acetyl-phenylalanine methyl and allyl esters derivatives. These
derivatives were submitted to an enzymatic kinetic resolution via interesterification reaction. After
screening with various commercial lipases, it was found that only RML was able to promote the
kinetic resol tion (Scheme 29). Several parameters wer studied and the best r action conditions were
obtained in the presence of butyl butyrate as an interesterification agent, with an enzym :substrate
ratio of 2:1 (w/w), at 30 ˝C, and MeCN as a solvent. Most derivatives (S-configuration) were obtained
with >99% ee and E > 200 [48].
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3.19. (S)-1-(2-Furyl)ethanol 
The (S)-1-(2-furyl)ethanol is used as an important building block for the synthesis of various 
natural products such as flavonoids, polyketide antibiotics and carbohydrate derivatives. This 
intermediate was obtained by lipase-catalyzed kinetic resolution of racemic 1-(2-furyl)ethanol. After 
commercial lipases screening in n-heptane as a solvent and 2 h of reaction time, the lipase from 
Candida antarctica B (Novozym 435) was the most efficient enzyme, leading to higher conversion (c 47%) 
than those observed with the other evaluated enzymes, RM IM Lipozyme (c 1.8%) and Lipozyme TL 
IM (c 1.5%). Various parameters were studied before establishing the best reaction conditions (vinyl 
acetate as the acyl donor, n-heptane as the solvent, a stirring speed of 300 rpm, 5 mg of enzyme loading at 
60 °C). In these conditions, the (S)-1-(2-furyl)ethanol was obtained with c 47% and 89% ee (Scheme 30). 
The study of the reuse of the biocatalyst was also performed, and it was shown that it can be recycled 
three times with a small decrease in conversion from 47.0% to 44.5% [49]. 
 
Scheme 30. Kinetic enzymatic acylation of the rac-1-(2-furyl)ethanol to produce the (S)-alcohol, an 
important building block for the synthesis of various natural products [49]. 
3.20. Ascorbyl Ester Derivatives 
Ascorbic acid (Asc) is a very important natural antioxidant, but with limited industrial 
application because of its hydrophilic nature. Alternatively, ascorbyl esters are considered 
antioxidants to be used in hydrophobic formulations [50]. A series of lipophilic esters derived from 
ascorbic acid was prepared by using lipase from Staphylococcus xylosus immobilized on silica aerogel. 
The regioselective enzymatic esterification of Asc with seven carboxylic acids (acetic acid and six fatty 
acids) was performed in MeCN and 2-methyl-2-propanol (co-solvent) for 72 h. Yields varied with the 
length of the fatty acid chain, and the best result was obtained on the preparation of the short chain 
derivative ascorbyl acetate (82.6 % yield), as seen in Scheme 31. All Asc derivatives were submitted 
to some bioassays (antibacterial, antioxidant, and antileishmanial), and the results suggested them as 
candidates to be used in the cosmetic and pharmaceutical industries [51]. 
 
Scheme 31. Kinetic enzymatic acylation of the ascorbic acid (Asc) to produce ascorbyl esters derivatives [51]. 
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commercial lipases screening in n-heptane as a solvent and 2 h of reaction time, the lipase from
Candida antarctica B (Novozym 435) was the most efficient enzyme, leading to higher conversion
(c 47%) than those observed with the other evaluated enzymes, RM IM Lipozyme (c 1.8%) and
Lipozyme TL IM (c 1.5%). Various parameters were studied before establishing the best reaction
conditions (vinyl acetate as the acyl donor, n-heptane as the solvent, a stirring speed of 300 rpm,
5 mg of enzyme loading at 60 ˝C). In these conditions, the (S)-1-(2-furyl)ethanol was obtained with
c 47% and 89% ee (Scheme 30). The study of the reuse of the biocatalyst was also performed, and
it was shown that it can be recycled three times with a small decrease in conversion from 47.0% to
44.5% [49].
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3.21. Key Intermediates of Stagonolide E, Pyrenophorol and Decarestrictine L
Enantiomerically pure hept-6-ene-2,5-diol derivatives were prepared by lipase-catalyzed
acetylation of the corresponding racemates, and used as key intermediates in the synthesis
of the bioactive compounds Stagonolide E, Pyrenophorol and Decarestrictine L (Scheme 32),
all of them isolated from filamentous fungi. Racemic 6-methyl-5-hepten-2-ol was resolved by
acetylation with Novozym 435, vinyl acetate in hexane at room temperature, and yielded both
the (R)-acetate and (S)-alcohol with 98% ee (E > 195) after 50% conversion. The (R)-alcohol was
also produced by treatment of (R)-acetate with LiAlH4. Then, both the (R)- and (S)-alcohols
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were submitted, individually, to some chemical steps that included protection of the hydroxyl
group with tert-butyldiphenylsilyl (TBDPS), ozonolysis and reaction of the obtained aldehydes with
vinylmagnesium bromide, providing the allylic alcohols (3RS,6R) and (3RS,6S). A similar protocol
was used in the enzyme-catalyzed acylation of these allylic alcohols (Scheme 32). In this case, both
key intermediates (3S,6R)-acetate and (3R,6S)-alcohol were obtained with high enantioselectivity
(E > 195), c 50%. The enantiomerically pure (3R,6S)-alcohol was used as an intermediate in the
synthesis of Stagonolide E. The chemoenzymatic synthesis of Pyrenophorol and Decarestrictine L
involved the enantiomericaly pure allylic (3S,6R)-acetate as key intermediate (Scheme 32) [52].
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3.22. Key Intermediates of Macrolide Antibiotic (−)-A26771B 
The chemoenzymatic synthesis of the macrolide antibiotic (−)-A26771B involved the lipase-catalyzed 
acylation for resolving both a methylcarbinol and an allylic alcohol in order to establish the two 
stereogenic centers of the target molecule. A series of commercial lipases were investigated on the 
acetylation of the rac-methylcarbinol (tridec-12-en-2-ol) with vinyl acetate in hexane or DIPE at 25 °C. 
The best result was achieved when Novozym 435 (lipase B from Candida antarctica immobilized on 
acrylic resin) was used as the biocatalyst and DIPE as the solvent. This condition yielded  
(S)-methylcarbinol (96% ee) and the corresponding (R)-acetate (92% ee) after 2 h (c 51%), as seen in 
Scheme 33a. The same condition was used for the acetylation of the rac-allylic alcohol (Scheme 33b), 
which produced (3R,13R)-alcohol (98% ee) and (3S,13R)-acetate (95% ee) after 6 h (c 50%) [53]. 
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stereogenic centers of t e targ t molecule. A series of commerci l lipases were investigated on the
acetylation of the rac-methylcarbinol (tridec-12-en-2-ol) with vinyl acetate in h xane or DIPE at 25 ˝C.
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on acrylic resin) was used as the biocatalyst and DIPE as the solvent. This condition yielded
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commercially available lipases were screened, and the highest yield (99.1%) of the TMHQ-1-MA was 
obtained using Lipozyme RM IM (lipase from Rhizomucor miehei). No activity was observed when 
using lipase A (from Aspergillus niger) as an enzyme. Except for Lipozyme 435 (CAL-B, lipase B from 
Candida antarctica immobilized on macroporous polyacrylate resin), all active enzymes showed 100% 
regioselectivity on the formation of TMHQ-1-MA. Several reaction parameters were investigated and 
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conditions, the enzyme was active even after 20 cycles. A Ping-Pong bi-bi mechanism with n-butanol 
inhibition was proposed based on the initial rate data and concentration profiles [54]. 
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3.24. Rasagiline Mesylate 
A straightforward chemoenzymatic synthesis of Rasagiline mesylate has been developed 
(Scheme 35). This drug is used in monotherapy of Parkinson patients at an early stage, and as an 
adjunct to moderate the advanced stage of the disease. The synthesis began with the chemical 
reduction of indanone to give rac-indanol in 86% yield. Then, rac-indanol was subjected to enzymatic 
kinetic resolution using the lipase from Thermomyces lanuginosus (TLL) immobilized on immobead-150 as 
a biocatalyst, hexane as an organic solvent, vinyl acetate as an acyl donor, at 35 °C and with 15 min of 
reaction time. In this case, (R)-indanyl acetate and (S)-indanol were obtained with >99% ee, c 50% and 
E > 200. Then, the (S)-indanol was subjected to a sequence of chemical steps, which included a 
Mitsunobu reaction, a Staudinger reaction, the introduction of the propargyl group and, finally, the 
reaction with methanesulfonic acid, which afforded Rasagiline mesylate. Immobilized lipase from  
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(Scheme 35). This drug is used in mon therapy of Parkinson patients at an early stag , and
as an adjunct to moderate the adva ced stage of the dise se. The synthesis began with the
chemical reduction of indanon to give rac-indanol in 86% yield. Then, rac-inda ol was subjected
to enzymatic kinetic resolution using the lipase from Thermomyces lanuginosus (TLL) immobilized on
immobead-150 as a biocatalyst, hexane as n organic solve t, vinyl acetate as an acyl donor, at 35 ˝C
and with 15 min of react on time. In this case, (R)-indanyl acetate and (S)-indanol were obtained with
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>99% ee, c 50% and E > 200. Then, the (S)-indanol was subjected to a sequence of chemical steps, which
included a Mitsunobu reaction, a Staudinger reaction, the introduction of the propargyl group and,
finally, the reaction with methanesulfonic acid, which afforded Rasagiline mesylate. Immobilized
lipase from T. lanuginosus was found to be an efficient biocatalyst to produce (S)-indanol with high
enantioselectivity (>99% ee, E > 200) in hexane, at 35 ˝C and 15 min. Additionally, this enzyme
was reused 10 times, maintaining both the activity and selectivity unchanged. This preparation of
Rasagiline mesylate can be considered an environmentally sustainable strategy, since it involved the
use of a biocatalyst that is commercially available, low-cost, stable, reusable for multiple reaction
cycles and highly enantioselective [55,56].
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Scheme 36. Enzymatic kinetic resolution of rac-N-Boc-HMTHQ to prepare the (R)- and (S)-3-methyl-
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Argatroban is an inhibitor of thrombim, the protease that plays a key role in blood coagulation 
and fibrinolysis. The diastereoisomeric mixture of epimers ((21R)- and (21S)-epimers) is used as an 
antithrombotic drug, but the (21S)-isomer is twice as potent as 21R. The chiral intermediates (R)- and 
(S)-3-methyl-1,2,3,4-tetrahydroquinoline are used for the preparation of the antithrombotic (21R)- 
and (21S)-Argatroban. These intermediates were prepared using 3-quinoline carboxylic acid as a 
starting material. After some chemical steps, the rac-3-(1’-hydroxymethyl)-1-tert-butyloxycarbonyl-
1,2,3,4-tetrahydroquinoline (rac-N-Boc-HMTHQ) was obtained, and subjected to kinetic resolution in 
the presence of lipase from Pseudomonas fluorescens (PFL), with toluene as a solvent and vinyl acetate 
as an acyl donor. After this procedure, the (S)-ester (>99% ee for c 30%–40%) and the (R)-alcohol (81% ee 
for c 55–65%) were obtained. For obtaining the enantiomerically enriched (R)-alcohol (>99% ee), a 
second kinetic resolution was performed under the aforementioned conditions using the (R)-alcohol 
(81% ee). In this case, the reaction was stopped at a conversion ranging from 30% to 45% (Scheme 36). 
The (S)-acetate (>99% ee) was converted into the corresponding (S)-alcohol by enzymatic hydrolysis 
in the presence of PFL. Subsequently, both (S)- and (R)-alcohol were subjected to a sequence of 
chemical steps which included tosylation, reaction with lithium aluminum hydride and removal of 
the Boc protecting group, leading to enantiomerically pure intermediates (S)- and (R)-3-methyl-
1,2,3,4-tetrahydroquinoline [57]. 
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3.25. Argatroban
Argatroban is an inhibitor of thrombim, the protease that plays a key role in blood coagulation
and fibrinolysis. The diastereoisomeric mixture of epimers ((21R)- and (21S)-epimers) is used as an
antithrombotic drug, but the (21S)-isomer is twice as potent as 21R. The chiral intermediates
(R)- and (S)-3-methyl-1,2,3,4-tetrahydroquinoline are used for the preparation of the antithrombotic
(21R)- and (21S)-Argatroban. These intermediates were prepared using 3-quinoline carboxylic acid as a
starting material. After some chemical steps, the rac-3-(1’-hydroxymethyl)-1-tert-butyloxycarbonyl-1,
2,3,4-tetrahydroquinoline (rac-N-Boc-HMTHQ) was obtained, and subjected to kinetic resolution in
the presence of lipase from Pseudomonas fluorescens (PFL), with toluene as a solvent and vinyl acetate
as an acyl donor. After this procedure, the (S)-ester (>99% ee for c 30%–40%) and the (R)-alcohol
(81% ee for c 55–65%) were obtained. For obtaining the enantiomerically enriched (R)-alcohol
(>99% ee), a second kinetic resolution was performed under the aforementioned conditions using
the (R)-alcohol (81% ee). In this case, the reaction was stopped at a conversion ranging from 30%
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to 45% (Scheme 36). The (S)-acetate (>99% ee) was converted into the corresponding (S)-alcohol by
enzymatic hydrolysis in the presence of PFL. Subsequently, both (S)- and (R)-alcohol were subjected
to a sequence of chemical steps which included tosylation, reaction with lithium aluminum hydride
and removal of the Boc protecting group, leading to enantiomerically pure intermediates (S)- and
(R)-3-methyl-1,2,3,4-tetrahydroquinoline [57].
3.26. Key Intermediate of the Paclitaxel Side Chain
The synthesis of a key intermediate for the Paclitaxel side chain, (2R,3S)-3-phenylisoserine,
was performed by kinetic enzymatic resolution of racemic N-hydroxymethylated cis-3-acetoxy-4-
phenylazetidin-2-one (rac-azetidin-2-one derivative), via acylation reaction (Scheme 37). Various
parameters were evaluated such as lipases from Burkholderia cepacia (PS IM), Candida antarctica A
(CAL-A), Pseudomonas fluorescens (lipase AK) and C. rugosa (lipase AY); acyl donors such as vinyl
acetate, vinyl butyrate and 2,2,2-trifluoroethyl butyrate; temperature (4, 25 and 50 ˝C) and organic
solvent (DIPE, toluene, TBME and 2-MeTHF). The best results were obtained in the presence of
lipase PS IM, DIPE as a solvent, vinyl butyrate as an acyl donor, at 25 ˝C. The reaction was
conducted with a higher amount of substrate (100 mg) and, after 20 min, the conversion reached
50%, with the formation of the diester (3R,4S) with >99% ee and the remaining substrate (3S,4R)
with 98% ee, and E > 200, with traces of a byproduct from the migration of the acyl group. Both
the (3R,4S)-diester and the remaining (3S,4R)-substrate were subjected to acid hydrolysis leading to
(2R,3S)-3-phenylisoserine hydrochloride with >99% ee (key intermediate for the Paclitaxel side chain)
and (2S,3R)-3-phenylisoserine hydrochloride with 98% ee [58].
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Scheme 37. Enzymatic kinetic resolution of racemic N-hydroxymethylated cis-3-acetoxy-4-
phenylazetidin-2-one (rac-azetidin-2-one derivative), affording the key intermediate for the Paclitaxel 
side chain, (2R,3S)-3-phenylisoserine [58].  
3.27. Piperidine Derivative 
The chiral compound (S)-4-(1-(3,4-dichlorophenyl)-2-methoxyethyl)piperidine is a novel triple-
reuptake inhibitor (inhibiting the reuptake of serotonin, norepinephrine and dopamine), which was 
created as a candidate for a novel antidepressant agent. Among the strategies to synthesize the 
aforementioned compound, it is possible to highlight the enzymatic kinetic resolution of racemic tert-
butyl 4-(1-(3,4-dichlorophenyl)-2-hydroxyethyl)piperidine-1-carboxylate (rac-alcohol) via acetylation 
in the presence of lipases [59]. A preliminary enzyme screening was conducted using 38 lipases, 
wherein the lipase from Pseudomonas sp. immobilized on diatomite (Amano Enzyme Inc.) gave the 
best E-value (E 243). Several solvents were evaluated such as DIPE, THF, acetone, MeCN, DMF and 
TBME. In this case, DIPE showed the best performance leading to an E-value of 525. Thus, the kinetic 
resolution was performed in the optimized conditions using lipase PS IM (from Pseudomonas sp.), 
vinyl acetate as an acyl donor and DIPE as a solvent, at 35 °C. After the reaction reached 48% 
conversion, the product (S)-ester was obtained with 96% ee and (R)-alcohol with >99% ee, and E > 200 
(Scheme 38). Then, after some chemical steps, the (S)-ester was converted into the triple-reuptake 
inhibitor (S)-4-(1-(3,4-dichlorophenyl)-2-methoxyethyl)piperidine with 96% ee. It is worth 
mentioning that the reaction was performed on a 10 g scale, and after 40 h it was necessary to add 
Scheme 37. Enzymatic kinetic resolution of racemic N-hydroxymethylated cis-3-acetoxy-4-
phenylazetidin-2-one (rac-azetidin-2-one derivative), affording the key intermediate for the Paclitaxel
side chain, (2R,3S)-3-phenylisoserine [58].
3.27. Piperidine Derivative
The chiral compound (S)-4-(1-(3,4-dichlorophenyl)-2-methoxyethyl)piperidine is a novel
triple-reuptake inhibitor (inhibiting the reuptake of serotonin, norepinephrine and dopamine),
which was created as a candidate for a novel antidepressant agent. Among the strategies to synthesize
the aforementioned compound, it is possible to highlight the enzymatic kinetic resolution of
racemic tert-butyl 4-(1-(3,4-dichlorophenyl)-2-hydroxyethyl)piperidine-1-carboxylate (rac-alcohol)
via acetylation in the presence of lipases [59]. A preliminary enzyme screening was conducted using
38 lipases, wherein the lipase from Pseudomonas sp. immobilized on diatomite (Amano Enzyme Inc.)
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gave the best E-value (E 243). Several solvents were evaluated such as DIPE, THF, acetone, MeCN,
DMF and TBME. In this case, DIPE showed the best performance leading to an E-value of 525.
Thus, the kinetic resolution was performed in the optimized conditions using lipase PS IM (from
Pseudomonas sp.), vinyl acetate as an acyl donor and DIPE as a solvent, at 35 ˝C. After the reaction
reached 48% conversion, the product (S)-ester was obtained with 96% ee and (R)-alcohol with
>99% ee, and E > 200 (Scheme 38). Then, after some chemical steps, the (S)-ester was converted into
the triple-reuptake inhibitor (S)-4-(1-(3,4-dichlorophenyl)-2-methoxyethyl)piperidine with 96% ee.
It is worth mentioning that the reaction was performed on a 10 g scale, and after 40 h it was necessary
to add additional lipase and vinyl acetate. After over 24 h of agitation, the kinetic resolution gave an
excellent enantioselectivity.
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Scheme 38. Enzymatic kinetic resolution of racemic tert-butyl 4-(1-(3,4-dichlorophenyl)-2-
hydroxyethyl)piperidine-1-carboxylate (rac-alcohol), affording the novel triple reuptake inhibitor (S)-
4-(1-(3,4-dichlorophenyl)-2-methoxyethyl)piperidine [59]. 
3.28. Tetrahydroquinolinol and Tetrahydrobenzoazepinol Derivatives 
Tetrahydroquinolin-4-ols and tetrahydro-1H-benzo[b]azepin-5-ols, in chiral form, are building 
blocks for drug candidates due to their promising biological activities. A series of racemic  
N-protected tetrahydroquinolin-4-ols were chemically prepared from 1,2,3,4-tetrahydroquinoline. 
Subsequently, the rac-N-Boc-tetrahydroquinolin-4-ol (R1 = H; R2 = Boc) was subjected to kinetic 
resolution in the presence of lipases, using TBME as a solvent and vinyl acetate as an acyl donor, at 
30 °C and for 8 h (n = 1, Scheme 39 and Table 4). Among the evaluated lipases (Amano lipase Type VII, 
CAL-A, Amano lipase A, Novozym 435, lipase RM IM and lipase TL IM), Novozym 435 lipase 
provided the highest enantioselectivity for the (S)-alcohol (98% ee) and the (R)-acetate (97% ee), c 50% 
and E > 200. Then, under the same conditions, various acyl donors were tested (vinyl chloroacetate, 
divinyl heptanedioate, vinyl hexanoate, vinyl undecanoate and vinyl 2,2-dimethylpropionate). In this 
case, vinyl chloroacetate was the most effective acyl donor, producing both (R)-ester and (S)-alcohol 
with >99% ee, c 50% and E > 200. Besides TBME, other solvents (DIPE, MeCN, toluene and n-hexane) 
were evaluated, but TBME proved to be more efficient in the kinetic resolution. After optimizing the 
reaction conditions (Novozym 435, TBME as a solvent, vinyl chloroacetate as an acyl donor, 30 °C, 8 h), 
the kinetic resolution was extended to the other racemic N-protected tetrahydroquinolin-4-ols 
containing substituent groups at the aromatic ring (C-6) and different N-protecting groups (Table 4). 
In general, the kinetic resolutions provided the (R)-esters ranging from 37% to 49% yields, 92% to 
>99% ee, and the (S)-alcohols ranging from 29% to 48% yields, 94% to >99% ee, with E-values ranging 
from 126 to >200. It is worth noting that the formation of any desired products was not observed 
when the substrate had the benzyl group linked to the nitrogen atom (n = 1; R1 = H; R2 = Bn), as seen 
in Scheme 39 and Table 4. In this same study, the authors conducted the kinetic resolution of racemic 
N-protected tetrahydro-1H-benzo[b]azepin-5-ols (R = Bz, 2-furoyl and Cbz), (n = 2, Scheme 39 and 
Table 4). As result, the kinetic resolutions produced the corresponding (R)-esters and (S)-alcohols in 
excellent yields (up to 44%) and enantioselectivity (ee up to 98% and E > 200) [60]. 
  
Scheme 38. Enzymatic kinetic resolution of racemic tert-butyl 4-(1-(3,4-dichlorophenyl)-2-
hydroxyethyl)piperidine-1-carboxylate (rac-alcohol), affording the novel triple reuptake inhibitor
(S)-4-(1-(3,4-dichlorophenyl)-2-methoxyethyl)piperidine [59].
3.28. Tetrahydroquinolinol and Tetrahydrobenzoazepinol Derivatives
Tetrahydroquinolin-4-ols and tetrahydro-1H-benzo[b]azepin-5-ols, in chiral form, are building
blocks for drug candidates due to their promising biological activities. A series of racemic N-protected
tetrahydroquinolin-4-ols were chemically prepared from 1,2,3,4-tetrahydroquinoline. Subsequently,
the rac-N-Boc-tetrahydroquinolin-4-ol (R1 = H; R2 = Boc) was subjected to kinetic resolution in the
presence of lipases, using TBME as a solvent and vinyl acetate as an acyl donor, at 30 ˝C and for
8 h (n = 1, Scheme 39 and Table 4). Among the evaluated lipases (Amano lipase Type VII, CAL-A,
Amano lipase A, Novozym 435, lipase RM IM and lipase TL IM), Novozym 435 lipase provided
the highest enantioselectivity for the (S)-alcohol (98% ee) and the (R)-acetate (97% ee), c 50% and
E > 200. Then, under the same conditions, various acyl donors were tested (vinyl chloroacetate,
divinyl heptanedioate, vinyl hexanoate, vinyl undecanoate and vinyl 2,2-dimethylpropionate). In this
case, vinyl chloroacetate was the most effective acyl donor, producing both (R)-ester and (S)-alcohol
with >99% ee, c 50% and E > 200. Besides TBME, other solvents (DIPE, MeCN, toluene and n-hexane)
were evaluated, but TBME proved to be more efficient in the kinetic resolution. After optimizing the
reaction conditions (Novozym 435, TBME as a solvent, vinyl chloroacetate as an acyl donor, 30 ˝C,
8 h), the kinetic resolution was extended to the other racemic N-protected tetrahydroquinolin-4-ols
containing substituent groups at the aromatic ring (C-6) and different N-protecting groups (Table 4).
In general, the kinetic resolutions provided the (R)-esters ranging from 37% to 49% yields, 92% to
>99% ee, and the (S)-alcohols ranging from 29% to 48% yields, 94% to >99% ee, with E-values ranging
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from 126 to >200. It is worth noting that the formation of any desired products was not observed
when the substrate had the benzyl group linked to the nitrogen atom (n = 1; R1 = H; R2 = Bn), as seen
in Scheme 39 and Table 4. In this same study, the authors conducted the kinetic resolution of racemic
N-protected tetrahydro-1H-benzo[b]azepin-5-ols (R = Bz, 2-furoyl and Cbz), (n = 2, Scheme 39 and
Table 4). As result, the kinetic resolutions produced the corresponding (R)-esters and (S)-alcohols in
excellent yields (up to 44%) and enantioselectivity (ee up to 98% and E > 200) [60].Int. J. Mol. Sci. 2015, 16, page–page 
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Scheme 39. Enzymatic kinetic resolution of the racemic compounds N-protected tetrahydroquinolin-
4-ols (n = 1) and N-protected tetrahydro-1H-benzo[b]azepin-5-ols (n = 2) to produce building blocks 
for drug candidates [60]. 
Table 4. Substrates used for the enzymatic kinetic resolution to produce tetrahydroquinolinol and 
tetrahydrobenzoazepinol derivatives [60]. 
Substrates n R1 R2 
rac-N-protect tetrahydroquinolin-4-ols 1 
H Boc 
Cl Boc 
Br Boc 
OMe Ac 
H CO2Ph 
H Cbz 
rac-N-protect tetrahydro-1H-benzo[b]azepin-5-ols 2 
H Bz 
H 2-furoyl 
H Cbz 
3.29. Aminohydroxypiperidine Derivatives 
The trans-3-amino-4-hydroxypiperidine moiety is present in the structures of some bioactive 
compounds, such as an inhibitor of non-receptor tyrosine kinase (Scheme 40) that is used for the 
treatment of auto-immune disorders. Enantiopure, orthogonally protected (3R,4R)-3-amino-4-
hydroxypiperidine acetate was obtained by lipase-mediated kinetic acylation of the corresponding 
racemate. The racemic trans-N-benzyl-3-(diallylamino)-4-hydroxypiperidine (trans- hydroxypiperidine 
derivative) was obtained by the regioselective opening of the epoxide at the rac-1-benzyl-3,4-
epoxypiperidine (rac-epoxide) with diallylamine. Later, it was subjected to the enzymatic 
transesterification reaction with vinyl acetate (5 eq.) as the acyl donor, lipases from Candida antarctica 
type A (lipase NZL-101) and C. antarctica B (Novozym 435), Burkholderia cepacia (PSL IM), Pseudomonas 
fluorescens (AK) and Thermomyces lanuginosus (TL IM), in TBME as the solvent, and at 30 °C. Although 
all lipases catalyzed the acylation of the substrate with the same stereochemical preference, (3R,4R)-
product and (3S,4S)-substrate, the conversions were moderate (11%–31%). Thus, the influence of 
different reaction parameters (organic solvent, temperature, and triethylamine as additive) was 
studied in order to improve the reaction rate using the lipases CAL-A and CAL-B. The best result was 
obtained by using CAL-B, TBME/Et3N (10:1) as the solvent, three days of reaction time, and at 45 °C. In 
this case, the kinetic resolution yielded the (3R,4R)-product and (3S,4S)-substrate with enantiomeric 
excess of >99% and 81%, respectively, c 45% and E > 200 (Scheme 40). It should be mentioned that 
when the reaction was performed without triethylamine as an additive, a significant decrease in the 
reaction rate was observed (from three to seven days) [61]. 
Sche e 39. Enzymatic kinetic resolution of the racemic compounds N-protected tetrahydroquinolin-4-ols
(n = 1) and N-protected tetrahydro-1H-benzo[b]azepin-5-ols (n = 2) to produce building blocks for
drug candidates [60].
Table 4. Substrates used for the enzymatic kinetic resolution to produce tetrahydroquinolinol and
tetrahydrobenzoazepinol derivatives [60].
Substrates n R1 R2
rac-N-protect tetrahydroquinolin-4-ols 1
H Boc
Cl Boc
r Boc
OMe Ac
H CO2Ph
Cbz
rac-N-protect tetrahydro-1H-benzo[b]azepin-5-ols 2
Bz
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3.29. Aminohydroxypiperidine Derivatives
The trans-3-amino-4-hydroxypiperidine moiety is present in the structures of some bioactive
compounds, such as an inhibitor of non-receptor tyrosine kinase (Scheme 40) that is used for the treatment
of auto-immune disorders. Enantiopure, orthogonally protected (3R,4R)-3-amino-4-hydroxypiperidine
acetate was obtained by lipase-mediated kinetic acylation of the corresponding racemate. The
racemic trans-N-benzyl-3-(diallylamino)-4-hydroxypiperidine (trans- hydroxypiperidine derivative)
was obtained by the regioselective opening of the epoxide at the rac-1-benzyl-3,4-epoxypiperidine
(rac-epoxide) with diallylamine. Later, it was subjected to the enzymatic transesterification reaction
with vinyl acetate (5 eq.) as the acyl donor, lipases from Candida antarctica type A (lipase NZL-101)
and C. antarctica B (Novozym 435), Burkholderia cepacia (PSL IM), Pseudomonas fluorescens (AK)
and Thermomyces lanuginosus (TL IM), in TBME as the solvent, and at 30 ˝C. Although all lipases
catalyzed the acylation of the substrate with the same stereochemical preference, (3R,4R)-product
and (3S,4S)-substrate, the conversions were moderate (11%–31%). Thus, the influence of different
reaction parameters (organic solvent, temperature, and triethylamine as additive) was studied in
order to improve the reaction rate using the lipases CAL-A and CAL-B. The best result was obtained
by using CAL-B, TBME/Et3N (10:1) as the solvent, three days of reaction time, and at 45 ˝C. In this
case, the kinetic resolution yielded the (3R,4R)-product and (3S,4S)-substrate with enantiomeric
excess of >99% and 81%, respectively, c 45% and E > 200 (Scheme 40). It should be mentioned that
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when the reaction was performed without triethylamine as an additive, a significant decrease in the
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Scheme 40. Enzymatic kinetic resolution of the racemic trans-hydroxypiperidine derivative to 
produce the orthogonally protected (3R,4R)-3-amino-4-hydroxypiperidine, which is present in the 
structure of an inhibitor of non-receptor tyrosine kinase [61]. 
3.30. Azole Derivatives 
The azole subunit is part of the structure of a number of drugs such as Econazole, Fluconazole, 
Ketoconalole, Miconazole, Voriconazole and Ravuconazole. It is noteworthy that cycloalkyl azoles 
have been described as potent antileishmanial agents. A new family of racemic trans- and cis-azole 
derivatives was prepared and submitted to a kinetic resolution through transesterification in the 
presence of lipases (Scheme 41). The kinetic resolution was conducted with the racemic trans-3-(1H-
imidazol-1-yl)-1,2,3,4-tetrahydronaphthalen-2-ol (rac-trans-3-imidazol THN) in the presence of vinyl 
acetate as the acyl donor and THF as the solvent (Scheme 41a and Table 5). Several lipases were 
evaluated, such as lipases from Candida antarctica B (CAL-B, immobilized by adsorption in Lewatit E), 
from C. antarctica A (CAL-A), from C. rugosa (CRL), lipase AK from Pseudomonas fluorescens, from  
P. cepacia (PSL), from Rhizomucor miehei (RML), porcine pancreatic lipase (PPL), and from 
Thermomyces lanuginosus (TLL). Among them, only PSL produced an appreciable degree of activity 
with good selectivity. Subsequently, several commercially available types of PSL were evaluated, and 
PSL-C I (immobilized onto a ceramic carrier) was the most efficient (with a ratio of 1:1 lipase/substrate 
in weight), producing (after 48 h at 30 °C) trans-(2R,3R)-acetate in 95% ee and trans-(2S,3S)-alcohol 
with 83% ee, c 46%, E-value of 102. PSL-C I was also the most efficient in the kinetic resolution of the 
cis-isomer. After 24 h at 45 °C, using the ratio 2:1 of lipase:substrate in weight, the cis-(2R,3S)-acetate 
(95% ee) and cis-(2S,3R)-alcohol (71% ee) were obtained with c 43% and an E-value of 83 (Scheme 41a 
and Table 5). The strategy used to prepare the chiral imidazole derivatives was used to 
enantioselectively obtain the trans- and cis-triazol compounds (Scheme 41b and Table 5). Again, PSL-C 
I was the most efficient enzyme to promote the kinetic resolution of both racemic trans- and cis-3-(1H-
1,2,4-triazol-1-yl)-1,2,3,4-tetrahydronaphthalen-2-ols (rac-trans- and rac-cis-3-triazol THN). The 
experiments were performed using THF as the solvent and vinyl acetate as the acyl donor, at 30 °C 
and 48 h. The reaction with the rac-trans- isomer provided the trans-(2R,3R)-acetate with 99% ee and 
trans-(2S,3S)-alcohol with 93% ee, c 48% and E > 200. In the case of the rac-cis-isomer, it was obtained 
from the cis-(2R,3S)-acetate with >99% ee and cis-(2S,3R)-alcohol with 29% ee, c 23% and E > 200 
(Scheme 41b and Table 5) [62]. Tetrahydronaphthylazoles are known to exhibit antileishmanial 
properties, which has inspired the authors [62] to resolve the racemate of trans- and cis-1-(1H-
imidazol-1-yl)-1,2,3,4-tetrahydronaphthalen-2-ols (rac-trans- and rac-cis-1-imidazol THN) using the 
same aforementioned enzymatic methodology. The kinetic resolutions of these isomers were 
conducted in THF as a solvent and vinyl acetate as an acyl donor, at 30 °C and for 48 h. The lipases 
CAL-B and PSL-C I were tested and the latter led to the best results. Thus, for the rac-trans-isomer, 
Scheme 40. Enzymatic kinetic resolution of the racemic trans-hydroxypiperidine derivative to
produce the orthogonally protected (3R,4R)-3-a ino-4-hydroxypiperidine, which is present in the
structure of an inhibitor of non-receptor tyrosine kinase [61].
3.30. Azole Derivatives
The azole subunit is part of the structure of a number of drugs such as Econazole, Fluconazole,
Ketoconalole, Miconazole, Voriconazole and Ravuconazole. It is noteworthy that cycloalkyl azoles
have been described as potent antileishmanial agents. A new family of racemic trans- and cis-azole
derivatives was prepared and submitted to a kinetic resolution through transesterification in the
presence of lipases (Scheme 41). The kinetic resolution was conducted with the racemic trans-3-
(1H-imidazol-1-yl)-1,2,3,4-tetrahydronaphthalen-2-ol (rac-trans-3-imidazol THN) in the presence of
vinyl acetate as the acyl donor and THF as the solvent (Scheme 41a and Table 5). Several lipases
were evaluated, such as lipases from Candida antarctica B (CAL-B, immobilized by adsorption in
Lewatit E), from C. antarctica A (CAL-A), from C. rugosa (CRL), lipase AK from Pseudomonas fluorescens,
from P. cepacia (PSL), from Rhizomucor miehei (RML), porcine pancreatic lipase (PPL), and from
Thermomyces lanuginosus (TLL). Among them, only PSL produced an appreciable degree of activity
with good selectivity. Subsequently, several commercially available types of PSL were evaluated,
and PSL-C I (immobilized onto a ceramic carrier) was the most efficient (with a ratio of 1:1
lipase/substrate in weight), producing (after 48 h at 30 ˝C) trans-(2R,3R)-acetate in 95% ee and
trans-(2S,3S)-alcohol with 83% ee, c 46%, E-value of 102. PSL-C I was also the most efficient in the
kinetic resolution of the cis-isomer. After 24 h at 45 ˝C, using the ratio 2:1 of lipase:substrate in weight,
the cis-(2R,3S)-acetate (95% ee) and cis-(2S,3R)-alcohol (71% ee) were obtained with c 43% and an
E-value of 83 (Scheme 41a and Table 5). The strategy used to prepare the chiral imidazole derivatives
was used to enantioselectively obtain the trans- and cis-triazol compounds (Scheme 41b and Table 5).
Again, PSL-C I was the most efficient enzyme to promote the kinetic resolution of both racemic
trans- and cis-3-(1H-1,2,4-triazol-1-yl)-1,2,3,4-tetrahydronaphthalen-2-ols (rac-trans- and rac-cis-3-triazol
THN). The experiments were performed using THF as the solvent and vinyl acetate as the acyl donor,
at 30 ˝C and 48 h. The reaction with the rac-trans- isomer provided the trans-(2R,3R)-acetate with
99% ee and trans-(2S,3S)-alcohol with 93% ee, c 48% and E > 200. In the case of the rac-cis-isomer,
it was obtained from the cis-(2R,3S)-acetate with >99% ee and cis-(2S,3R)-alcohol with 29% ee,
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c 23% and E > 200 (Scheme 41b and Table 5) [62]. Tetrahydronaphthylazoles are known to exhibit
antileishmanial properties, which has inspired the authors [62] to resolve the racemate of trans- and
cis-1-(1H-imidazol-1-yl)-1,2,3,4-tetrahydronaphthalen-2-ols (rac-trans- and rac-cis-1-imidazol THN)
using the same aforementioned enzymatic methodology. The kinetic resolutions of these isomers
were conducted in THF as a solvent and vinyl acetate as an acyl donor, at 30 ˝C and for 48 h.
The lipases CAL-B and PSL-C I were tested and the latter led to the best results. Thus, for the
rac-trans-isomer, both the trans-(1R,2R)-acetate in 96% ee and trans-(1S,2S)-alcohol with 85% ee
(c 43% and an E-value of 133) were obtained. In the case of the rac-cis-isomer, the compounds
cis-(1S,2R)-acetate and cis-(1R,2S)-alcohol with 98% ee (c 50% and E > 200) were obtained (Scheme 41c
and Table 5).
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Scheme 41. Enzymatic kinetic resolution of the racemic trans- and cis-3-imidazol THN (a), racemic 
trans- and cis-3-triazol THN (b) and racemic trans- and cis-1-imidazol THN (c) [62]. 
Table 5. Results from the enzymatic kinetic resolution of the racemic trans- and cis-3-imidazol THN (a), 
racemic trans- and cis-3-triazol THN (b) and racemic trans- and cis-1-imidazol THN (c) [62]. 
Scheme 41 Substrate c (%) 
eeP (%) 
Acetate 
eeS (%)  
Alcohol 
E 
a 
trans-3-imidazol THN 46 95 83 102 
rac-cis-3-imidazol THN 43 95 71 83 
b 
rac-trans-3-triazol THN 48 99 93 >200 
rac-cis-3-triazol THN 23 >99 29 >200 
c 
rac-trans-1-imidazol THN 43 96 85 133 
rac-cis-1-imidazol THN 50 98 98 >200 
3.31. Benzoin Derivative 
Chiral α-hydroxy ketones are important building blocks in the syntheses of several biologically 
active compounds such as pharmaceuticals, agrochemicals and pheromones. Aiming to obtain the 
(S)-benzoin butyrate, a study for the dynamic enzymatic kinetic resolution (DKR) of racemic benzoin 
via acylation was developed [63]; an efficient DKR is needed for competing with other biocatalytical 
approaches, such as the enantioselective reduction of benzyl ketones, which has been reported as a 
useful technique for preparing (S)-benzoins [64,65]. The reactions were conducted in batch or 
continuous mode using lipase from Pseudomonas stutzeri (lipase TL) immobilized on Accurel carrier 
MP1001 [63]. Various solvents were evaluated in relation to TL lipase activity such as toluene,  
2-MeTHF, 1,3-dioxolane, cyclopentyl methyl ether (CPME), as well as some solvents classified as 
deep eutectic solvents (DESs). At the same time, a study was conducted to verify the influence of the 
amount of water in the solvents on the enzyme activity. As result, dry CPME was the most efficient 
solvent for the catalytic activity of the lipase TL as well as for catalyst activity of Zr-TUD-1 (a three-
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Table 5. Results from the enzymatic kinetic resolution of the racemic trans- and cis-3-imidazol
THN (a), racemic trans- and cis-3-triazol THN (b) and racemic trans- and cis-1-imidazol THN (c) [62].
Scheme 41 Substrate c (%) eeP (%) Acetate eeS (%) Alcohol E
a trans-3-imidazol THN 46 95 83 102
rac-cis-3-imidazol THN 43 95 71 83
b
rac-trans-3-triazol THN 48 99 93 >200
rac-cis-3-triazol THN 23 >99 29 >200
c rac-trans-1-imidazol THN 43 96 85 133
rac-cis-1-imidazol THN 50 98 98 >200
3.31. Benzoin Derivative
Chiral α-hydroxy ketones are important building blocks in the syntheses of several biologically
active compounds such as pharmaceuticals, agrochemicals and pheromones. Aiming to obtain the
(S)-benzoin but rate, a study for the dynamic enzymatic kinetic resolution (DKR) of racem c benzoin
via acylation was developed [63]; an effi ient DKR is needed for competing with other biocatalytical
approaches, s ch as the enantiosel ctive reduction of benzyl ketones, which has been reported as
a useful echnique for pr paring (S)-benzoins [64,65]. The rea tions were conducted in b tch or
continuous mode u ing lip se from Pseudomonas stutzeri (lipase TL) immobilized on Accurel carrier
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MP1001 [63]. Various solvents were evaluated in relation to TL lipase activity such as toluene,
2-MeTHF, 1,3-dioxolane, cyclopentyl methyl ether (CPME), as well as some solvents classified as
deep eutectic solvents (DESs). At the same time, a study was conducted to verify the influence of
the amount of water in the solvents on the enzyme activity. As result, dry CPME was the most
efficient solvent for the catalytic activity of the lipase TL as well as for catalyst activity of Zr-TUD-1
(a three-dimensional mesoporous silicate containing zirconium), with this latter used for in situ
racemization of the (R)-benzoin. The DKR of rac-benzoin, in batch mode, was carried out at 50 ˝C
in the presence of vinyl butyrate (6 eq.) as the acyl donor, dried CPME as the solvent, Zr-TUD-1 as
the catalyst and immobilized TL lipase as the enzyme. After 5 h, (S)-benzoin butyrate (c 98.2% and
99% ee) was obtained. Subsequently, the DKR of rac-benzoin was investigated in a continuous flow
system in the presence of vinyl butyrate (3 eq.), TL lipase, and Zr-TUD-1 in CPME. After 25 h, the
(S)-benzoin butyrate was obtained with a maximum conversion of 40%, decreasing to 11% at 76 h.
The enantiomeric excess values (ee) of the (S)-benzoin butyrate were ě98% throughout the process
(Scheme 42) [63].
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4. Complementary Approaches: Hydrolysis and Esterification
4.1. Acetonide Derivatives
The compound ((R)-2,2,4-trimethyl-1,3-dioxolan-4-yl)-methanol ((R)-acetonide alcohol), a chiral
intermediate used in the synthesis of some bioactive compounds, was prepared in high ee by the
enzymatic resolution of its rac mate form (Scheme 3a). In is case, both succinic anhydride
and vinyl laurate were used as acyl donors, and Amano PS-D lipase was the selected enzyme.
The (S)-acetonide alcohol was selectively acylated (with TBME as the solvent) and yielded the
(R)-acetonide semiester (with succinic anhydride as the acyl donor) and (R)-acetonide ester (with
vinyl laurate as the acyl donor), besides the remaining (R)-acetonide alcohol (Scheme 43a). The
(R)-acetonide alcohol was also obtained by kinetic resolution of the corresponding racemic ester
via hydrolysis using CAL-B (Novozym 435) as the lipase, and t-BuOH:H2O (9:1) as the solvent
(Scheme 43b) [67].
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4.2. Vitamin D Analogues
Vitamin D plays a vital role in maintaining calcium levels within the normal range. Analogues of
vitamin D have been prepared in order to obtain compounds with calcemic activity. Such analogues
were obtained by separation of a mixture of epimers (at C-24 containing an OH group) using two
approaches, (a) enzymatic kinetic resolution via esterification or (b) solvolysis of the corresponding
esters, and the epimer of interest (with biological activity) was the one with S configuration. In the
first approach (route a), the esterifications were carried out using an acylating agent (especially vinyl
acetate), organic solvent (especially hexane or DIPE) and lipases from Alcalagenes sp. or Pseudomonas sp.
(in free or immobilized form). The reactions were monitored by HPLC to ensure diastereomeric
excess amounts in the range of 80%–95%. In this case, the desired epimer is the remaining alcohol
(S configuration at C-24), as seen in Scheme 44a. In the second approach (route b), esterified vitamin
D analogues have undergone alcoholysis or hydrolysis in the presence of the same lipases used in
route a. These reactions gave a diastereomeric excess in the range of 80%–95% (Scheme 44b) and the
desired epimer was the non-hydrolyzed (S)-acetate [68].
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4.3. Arylalkylcarbinol Derivatives
Candida antarctica lipase B (CAL-B, Novozym 435) was investigated as a biocatalyst in
the complementary preparation of (S)- and (R)-arylalkylcarbinol acetates, which are important
intermediates for the syntheses of several compounds with industrial application. This enzyme was
used in the hydrolysis of racemic arylalkylcarbinyl acetates (route a) and produced both (R)-alcohols
and (S)-acetates in high enantioselectivities. Then, the mixture of these compounds was subjected
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to Mitsunobu reaction to yield the (S)-acetates as the only products (94% ee (n = 1) and 99% ee
(n = 2)), as seen in Scheme 45a. The complementary process was conducted using CAL-B on the
catalyzed acylation of the rac-arylalkylcarbinols, producing the (S)-alcohols and (R)-acetates in high
enantioselectivities (route b). Subsequently, these mixtures were submitted to a Mitsunobu reaction
and provided only the (R)-acetates (99% ee (n = 1 or 2)), as seen in Scheme 45b [69].
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4.4. Key Intermediate of Levofloxacin
The benzoxazine moiety is part of the structures of a series of molecules with biological
activities such as antibacterial, anticancer, antifungal and antimicrobial. A number of 1,4-benzoxazine
derivatives (with or without substituents at the aromatic ring) were prepared by a combination
of chemical steps and lipase-mediated kinetic resolution [70]. The enzymatic step was conducted
with rac-1-(2-nitrophenoxy)propan-2-ols (rac-alcohols), via acylation (route a), and with the
corresponding rac-acetates, via hydrolysis (route b), as seen in Scheme 46. These two approaches
are considered complementary lipase-catalyzed processes. The process of kinetic resolution
via acetylation was first evaluated using the rac-1-(2-nitrophenoxy)propan-2-ol as a substrate,
in the presence of vinyl acetate as an acyl donor, TBME as a solvent, at 30 ˝C and with 5 h of reaction
time. After screening lipases from Candida antarctica (CAL-A), from Pseudomonascepacia
(PSL C-I), from C. antarctica B (CAL-B) and from Rhizomucor miehei in immobilized form (RML
IM), it was found that the latter (RM IM) was the most efficient. In the aforementioned
conditions, the (R)-acetate (94% ee) and the remaining (S)-alcohol (89% ee) were obtained with
c 48%. The study was extended to the rac-alcohols with substituents at the aromatic ring
(4-F, 4-OMe and 5-Me), leading to the (R)-acetates (93%–95% ee) and the remaining (S)-alcohols
(89%–94% ee) with c 48%–50% and E-values ranging from 103 to >200 (Scheme 46a and Table 6).
By a sequence of reactions, the (R)-3-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine derivatives
((R)-3-methyl-1,4-benzoxazines) were synthesized from the (S)-alcohols. The second approach
(route b) was related to the resolution of the corresponding rac-acetates via hydrolysis reaction.
In this case, the reactions were carried out in the presence of RML IM, at 30 ˝C, using
TBME and water (5 eq.) as solvents. After 52 h, the (R)-alcohols (96% to >99% ee) and the
remaining (S)-acetates (91%–97% ee) were obtained with c 48%–50% and E > 200 (Scheme 46b and
Table 6). Due to the successful strategies for obtaining the chiral 1,4-benzoxazines, the authors
performed the production of the (S)-7,8-difluoro-3-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine,
precursor of the potent antibacterial Levofloxacin (Scheme 46c). Then, the kinetic resolution of
the rac-1-(2,3-difluoro-6-nitrophenoxy)propan-2-yl acetate was performed, via hydrolysis in the
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presence of lipase RM IM, leading to the (R)-alcohol (>99% ee) and the remaining (S)-acetate
(84% ee) with c 46%. Subsequently, after several chemical steps, the (R)-alcohol was converted into
the (S)-7,8-difluoro-3-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine (36% yield, >99% ee) Levofloxacin
precursor [70].
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Scheme 46. Enzymatic kinetic resolution of racemic alcohols 1-(2-nitrophenoxy)propan-2-ols
via acetylation (a) or via hydrolysis (b) of the corresponding racemic acetates. Producti f
(S)-7,8-difluoro-3-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine precursor of the antibacterial drug
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Table 6. Results from the enzymatic kinetic resolution of racemic alcohols 1-(2-nitrophenoxy)
propan-2-ols via acetylation (a) or via hydrolysis (b) of the corresponding racemic acetates [70].
Scheme 46
Acetates Alcohols
c (%) Eee (%) Yield (%) ee (%) Yield (%)
a 93–95 45–47 89–94 44–48 48–50 103–>200
b 91–97 41–48 96–>99 44–47 48–50 >200
5. Conclusions
Recent examples of the use of lipases in the preparation of enantiomerically pure active
pharmaceutical ingredients (APIs) and their intermediates were reviewed, confirming the importance
of these enzymes in obtaining compounds with high added value. Most reported biocatalytic
processes refer to kinetic resolutions of racemic substrates, which occur under mild conditions with
a high degree of regio- or enantioselectivity. Among the examples presented, the action of lipases
can be seen in a wide range of substrates with varied structures such as aromatic, heteroaromatic
(containing atoms of nitrogen, sulfur, chlorine, etc.), as well as aliphatic with either open or cyclic
chain (branched or not). The substances produced by the action of lipases, in the examples herein,
are pharmaceutical intermediates or drugs, which makes the biocatalytic process of great interest in
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the pharmaceutical industry. Additionally, it was also possible to confirm the versatility of lipases
for acting in either aqueous medium or organic solvents for the hydrolysis of esters, the acylation of
alcohols or the esterification of carboxylic acid, allowing the production of the desired stereoisomer.
It highlights the operational simplicity, as it is not necessary to add cofactors in the reaction system,
and the ease of finding a wide range of commercially available and relatively low-cost lipases. The
use of immobilized lipase often allows the reuse of the enzymatic system for several cycles, making
the process more effective and economically viable. In summary, it is clear that lipases will continue
to be an excellent alternative for obtaining biologically active compounds.
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